Priorities for the Priority Review Voucher.
Journal Article (Journal Article)
The U.S. Congress created the priority review voucher program in 2007 to encourage development of drugs for neglected diseases. Under the voucher program, the developer of a drug for a neglected or rare pediatric disease that is approved by the U.S. Food and Drug Administration receives a bonus priority review voucher for another drug. As of 2016, four vouchers have sold for an average price of $200 million. Recent experience with the voucher program indicates strengths and weaknesses of the program, as well as a need for legislative changes.
Full Text
Duke Authors
Cited Authors
- Ridley, DB
Published Date
- January 2017
Published In
Volume / Issue
- 96 / 1
Start / End Page
- 14 - 15
PubMed ID
- 27573624
Pubmed Central ID
- PMC5239680
Electronic International Standard Serial Number (EISSN)
- 1476-1645
International Standard Serial Number (ISSN)
- 0002-9637
Digital Object Identifier (DOI)
- 10.4269/ajtmh.16-0600
Language
- eng